

PERNIX THERAPEUTICS HOLDINGS, INC.
Form 8-K
March 21, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2014

PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Maryland
(State or other jurisdiction
of incorporation)

001-14494
(Commission File
Number)

33-0724736
(IRS Employer Identification
No.)

10863 Rockley Road
Houston, TX
(Address of principal executive
offices)

77099
(Zip Code)

Registrant's telephone number, including area code: (832) 934-1825

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective March 18, 2014, Michael Pearce resigned from the Company's Board of Directors after a period of valuable transition. His resignation did not relate to any disagreement with the Board of Directors (the "Board") or management of the Company or disagreement with respect to matters related to the operations, policies or practices of the Company. Mr. Pearce was not an independent director under Nasdaq Marketplace rules. To further assist with the transition, Mr. Pearce will continue to provide consulting services to the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PERNIX THERAPEUTICS HOLDINGS, INC.

Dated: March 21, 2014

By: /s/ Tracy S. Clifford
Tracy S. Clifford
Principal Financial and Accounting
Officer